Exenatide

Drug Profile

Exenatide

Alternative Names: AC 2993; AC002993; AC2993A; Byetta; exendin 4; LY2148568

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Amylin Pharmaceuticals
  • Developer AstraZeneca; Eli Lilly; Regional and University Hospital of Besancon
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II/III Metabolic disorders
  • Phase II Obesity

Most Recent Events

  • 11 Oct 2016 Exenatide licensed to Hongkong Sansheng for commercialisation in China
  • 15 Mar 2016 Biomarkers information updated
  • 09 Feb 2015 Phase-III development for Type 2 diabetes mellitus (In adolescents) is ongoing in USA, India, Mexico and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top